AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition

Predictive Analytics and AI: Reducing Emergency Room Visits through Enhanced Triage and Resource Allocation

Predictive analytics, Artificial intelligence (AI), Emergency department (ED) visits, Triage, Resource allocation, Machine learning (ML), Healthcare optimization